Barinthus Biotherapeutics Reports Reduced Losses and Strategic Merger Plans for 2026

Barinthus Biotherapeutics plc reported a significant reduction in its financial losses for the second quarter of 2026, with a net loss of $10.6 million compared to $21.1 million in the same period of 2025. For the first half of 2026, the company recorded a net loss of $16.1 million, down from $40.8 million in the prior year. This improvement is attributed to a decrease in total operating expenses, which fell to $11.0 million for the quarter and $17.1 million for the six months, down from $23.3 million and $44.3 million, respectively. The reduction in expenses was primarily driven by lower research and development costs, which decreased by 49% year-over-year for the quarter and by 53% for the half-year period.

The company’s cash and cash equivalents stood at $59.6 million as of June 30, 2026, a decrease from $71.9 million at the end of 2025. This decline was influenced by cash used in operating activities, which totaled $11.5 million for the first half of 2026, compared to $33.0 million in the same period of 2025. The decrease in cash outflow reflects the company's strategic shift to prioritize its immunology and inflammation pipeline, leading to a reduction in spending on legacy programs in infectious diseases and oncology.

Barinthus has also made strategic moves to enhance its operational capabilities, including the ongoing Phase 1 clinical trial of its lead candidate, VTP-1000, aimed at treating celiac disease. The company is actively pursuing a merger with Clywedog Therapeutics, which is expected to close in the second half of 2026. This merger is anticipated to create a combined entity focused on advancing a differentiated portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases. The merger agreement has been amended to provide additional flexibility in finalizing transaction terms, reflecting the company's commitment to enhancing its market position.

Operationally, Barinthus has streamlined its workforce and reduced its headcount, which has contributed to lower general and administrative expenses. The company reported a decrease in personnel-related costs, which fell significantly due to the closure of its U.K. laboratory and the associated reduction in indirect costs. As of June 30, 2026, Barinthus had 40,848,893 ordinary shares outstanding, with a weighted average net loss per share of $0.26 for the quarter.

Looking ahead, Barinthus anticipates continued operating losses as it advances its product candidates through clinical development and seeks regulatory approvals. The company expects to require additional funding to support its operations and development activities, with plans to finance future cash needs through public or private equity offerings, debt financings, or collaborations. The management remains optimistic about the potential of its proprietary SNAP-TI platform and the upcoming merger, which they believe will position the company for future growth and success in the biopharmaceutical market.